# Genexine, Inc. clinical trials: 36 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 36 trials with Genexine, Inc. as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Genexine, Inc.: 36 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/genexine-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 36
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 36, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 8, 2024 | NCT06490939 | Clinical Trial of Efepoetin Alfa in Healthy Subjects | Genexine, Inc. | Phase 1 | Completed | Healthy | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06490939) |
| June 20, 2024 | NCT06466785 | A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis | Genexine, Inc. | Phase 3 | Recruiting | Anemia of Chronic Kidney Disease | 429 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06466785) |
| January 13, 2022 | NCT05191784 | GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients | Genexine, Inc. | Phase 2 | Unknown | Recurrent Glioblastoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05191784) |
| October 5, 2021 | NCT05067946 | Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines | Genexine, Inc. | Phase 2/3 | Withdrawn | SARS-CoV2 Infection | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05067946) |
| June 7, 2021 | NCT04915989 | Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals | Genexine, Inc. | Phase 1 | Completed | SARS-CoV-2 | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04915989) |
| January 29, 2021 | NCT04730427 | Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19 | Genexine, Inc. | Phase 1 | Terminated | Covid19 | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04730427) |
| January 20, 2021 | NCT04715997 | Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults | Genexine, Inc. | Phase 1/2 | Completed | SARS-CoV-2 | 185 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04715997) |
| June 24, 2020 | NCT04445389 | Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults | Genexine, Inc. | Phase 1/2 | Terminated | SARS-CoV-2 | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04445389) |
| March 6, 2020 | NCT04298749 | Safety and Tolerability of GX-P1 in Healthy Male Volunteers | Genexine, Inc. | Phase 1 | Completed | Autoimmune Diseases | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04298749) |
| February 28, 2020 | NCT04289155 | Individual Patient Compassionate Use of GX-I7 | Genexine, Inc. | Not applicable | No longer available | Glioblastoma, High Grade Glioma, Recurrent Glioblastoma, Melanoma, Advanced Cancer | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04289155) |
| August 22, 2019 | NCT04065087 | Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma | Genexine, Inc. | Phase 1/2 | Withdrawn | Newly Diagnosed Glioblastoma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04065087) |
| May 23, 2019 | NCT03962010 | A Phase 2, 12-Week, Double-Blind, Efficacy and Safety of GX-G6 in Patients With Uncontrolled Type 2 Diabetes Mellitus | Genexine, Inc. | Phase 2 | Unknown | Type 2 Diabetes Mellitus | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03962010) |
| November 26, 2018 | NCT03752723 | Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899) | Genexine, Inc. | Phase 1/2 | Completed | Triple Negative Breast Cancer | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03752723) |
| November 7, 2018 | NCT03733587 | GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors | Genexine, Inc. | Phase 1 | Completed | Solid Tumor | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03733587) |
| August 29, 2018 | NCT03651466 | Safety and Tolerability of GX-G6 in Healthy Male Subjects | Genexine, Inc. | Phase 1 | Completed | Diabetes Mellitus | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03651466) |
| August 7, 2018 | NCT03619239 | Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma | Genexine, Inc. | Phase 1 | Completed | Newly Diagnosed Glioblastoma | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03619239) |
| March 27, 2018 | NCT03478995 | Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors | Genexine, Inc. | Phase 1 | Completed | Locally Advanced or Metastatic Solid Tumors | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03478995) |
| February 23, 2018 | NCT03444376 | The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer | Genexine, Inc. | Phase 1/2 | Completed | Cervical Cancer | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03444376) |
| October 16, 2017 | NCT03309891 | Dose Finding Study of GX-H9 in Paeditaric Patients With Growth Hormone Deficiency | Genexine, Inc. | Phase 2 | Completed | Growth Hormone Deficiency | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03309891) |
| September 8, 2017 | NCT03276988 | Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients | Genexine, Inc. | Phase 1/2 | Completed | Total Thyroidectomy, Near-total Thyroidectomy | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03276988) |
| May 9, 2017 | NCT03144934 | Safety and Tolerability of GX-I7 in HPV-infected Female Volunteers | Genexine, Inc. | Phase 1 | Completed | Human Papillomavirus | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03144934) |
| October 27, 2016 | NCT02946606 | A Clinical Study in AGHD to Assess Safety, Tolerability and Efficacy of GX-H9 | Genexine, Inc. | Phase 2 | Completed | Adult Growth Hormone Deficiency | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02946606) |
| August 9, 2016 | NCT02860715 | Clinical Trial of GX-I7 in Healthy Volunteers | Genexine, Inc. | Phase 1 | Completed | Healthy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02860715) |
| November 4, 2015 | NCT02596243 | Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E) | Genexine, Inc. | Phase 2 | Unknown | Cervical Intraepithelial Neoplasia | 134 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02596243) |
| April 8, 2015 | NCT02411019 | Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation | Genexine, Inc. | Observational | Unknown | Cervical Intraepithelial Neoplasia 3 | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02411019) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 17 |
| Phase 1/2 | 6 |
| Phase 2 | 7 |
| Phase 2/3 | 1 |
| Phase 3 | 1 |
| Not applicable | 2 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 24 |
| Unknown | 6 |
| Withdrawn | 2 |
| Terminated | 2 |
| No longer available | 1 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Uterine Cervical Dysplasia | 5 |
| Hepatitis B, Chronic | 3 |
| Glioblastoma | 2 |
| Dwarfism, Pituitary | 2 |
| COVID-19 | 2 |
| Papillomavirus Infections | 2 |
| Hepatitis, Chronic | 1 |
| Virus Diseases | 1 |
| DNA Virus Infections | 1 |
| Hepatitis B | 1 |
| Chronic Disease | 1 |
| Glioma | 1 |
| Melanoma | 1 |
| Anemia | 1 |
| Renal Insufficiency, Chronic | 1 |
| Head and Neck Neoplasms | 1 |
| HIV Infections | 1 |
| Acquired Immunodeficiency Syndrome | 1 |
| Diabetes Mellitus, Type 2 | 1 |
| Autoimmune Diseases | 1 |
| Triple Negative Breast Neoplasms | 1 |
| Breast Neoplasms | 1 |
| Thyroid Neoplasms | 1 |
| Neoplasms | 1 |
| Uterine Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Lawn care companies in the United States](https://specstream.ai/data/businesses/lawn-care-companies/united-states)
- [Excavation contractors in the United States](https://specstream.ai/data/businesses/excavation-contractors/united-states)
- [British restaurants in the United States](https://specstream.ai/data/businesses/british-restaurants/united-states)
- [Vehicle manufacturers in the United States](https://specstream.ai/data/businesses/vehicle-manufacturers/united-states)
- [Private schools in the United States](https://specstream.ai/data/businesses/private-schools/united-states)
- [Kosher restaurants in the United States](https://specstream.ai/data/businesses/kosher-restaurants/united-states)
